BIOMARIN PHARMACEUTICAL INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 80.4 USD | +0.94% |
|
-1.75% | -16.61% |
Presenter SpeechBrian Mueller (Executives)As Gena mentioned, I'll start with just a few slides...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
Pharmaceuticals
Calendar
2024-05-21
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
80.4
USD
Average target price
109.3
USD
Spread / Average Target
+35.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.61% | 15.27B | |
| +0.10% | 91.42B | |
| +2.76% | 41.08B | |
| -9.06% | 34.26B | |
| +53.99% | 25.27B | |
| -9.14% | 12.81B | |
| -12.11% | 11.6B | |
| -43.61% | 11.42B | |
| +3.67% | 9.16B | |
| -6.90% | 8.22B |
- Stock Market
- Equities
- BMRN Stock
- News BioMarin Pharmaceutical Inc.
- Transcript : BioMarin Pharmaceutical Inc. Presents at Barclays Global Healthcare Conference, Mar-15-2023 09